TRIBUNE-REVIEW — IDM's Amy Hartman said the early results from vaccine trials have her feeling more optimistic than she’s been throughout the pandemic. But, she cautioned, “it’s important to keep in mind that vaccines aren’t necessarily a finite ‘solution’ but they are an important step toward controlling the pandemic.” In the meantime, continuing mitigation efforts—staying physically apart, wearing masks, and washing hands—remain vital.
Peter Salk was 11 years old when a University of Pittsburgh team led by his father, the late Jonas Salk, created the inactivated poliovirus vaccine. The day of the 1955 announcement that the vaccine was safe, effective and potent, “everything just went crazy,” he recalls. “There were so many calls from reporters that we ended up having to get an answering service. Imagine how embarrassing that would be for a sixth grader.” Today, at 76, he’s bac...
"I utilize all aspects of my Pitt Public Health training in my current position. As a consultant, I often work on multidisciplinary teams to solve clients’ unique problems related to human health risk management. I am grateful for the diversity of coursework, training, and other applied opportunities afforded to me as a Pitt Public Health student, because I feel like those opportunities have allowed me to make meaningful contributions to the tea...
Nicholas V. Resciniti received his MPH with a concentration in infectious disease management, intervention, and community practice from Pitt Public Health in 2016. Currently, he is pursing his PhD in epidemiology from the University of South Carolina, with his dissertation focusing on microbiome disruption and the longitudinal association with cognitive impairment and dementia. His research focus is related to understanding the biological underp...
Alexander Sundermann is a clinical research coordinator and a DrPH student in epidemiology at Pitt Public Health. As a doctoral student and clinical research coordinator, Sundermann works in the Microbial Genomic Epidemiology Laboratory (MiGEL). He and the MiGEL team are working with experts at the University of Pittsburgh Medical Center (UPMC) and Carnegie Mellon University to build an Enhanced Detection System for Healthcare Associated Transmi...
TIMES OBSERVER - Pitt scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2. When Chinese scientists published the virus' genetic sequence January, Dimitrov’s team rapidly generated the virus’s receptor binding domain-part of the spike protein that attaches to human cells-and used it as “bait” to pan their multiple libraries of over 1 trillion human antibodies built over preced...
As part of the Conversations about COVID-19 seminar series, Mackey Friedman of IDM and BCHS joins IDM's Sarah Krier to discuss how the COVID-19 pandemic is affecting the lives of people living with HIV including their beliefs and attitudes about their healthcare needs and experiences.
THE CONVERSATION - Respiratory scientist Douglas Reed, IDM and Pitt Med, examined studies that have shown how the virus has spread, including at a call center in South Korea, a restaurant in China, and a choir practice in Washington state. “The evidence strongly suggests that airborne transmission happens easily and is likely a significant driver of this pandemic. It must be taken seriously as people begin to venture back out into the world.”
CUMBERLAND TIMES-NEWS - IDM’s John Mellors, UPMC’s chief of infectious diseases, said the biological molecule “is small, which means it penetrates into areas of the body where a full-sized antibody may not. It’s fully human, meaning that there’s no foreign material that’s likely to be rejected by the host… and it appears to be safe.” But he added, it's too early to talk about pricing of a treatment when it’s not (tested) in humans yet.
What we have learned during the summer of 2020 that puts SARS-CoV-2 into perspective with other emerging viruses and explores the current state of COVID-19 forecasting for the next few months. IDM's Amy Hartman talks what we know (and don't know) about SARS-CoV-2 and EPI's Donald Burke discusses the epidemiological and environmental factors that will shape the likely phases of the epidemic in our region.